Suchergebnisse - "TRAS"

PubPharm (194)

1

Insm1 regulates mTEC development and immune tolerance

enthalten in: Cellular & molecular immunology | 2023

von Tao, W. | Ye, Z. | Wei, Y. | +5

2

Role of protocol-guided perioperative care to enhance recovery after head and neck neoplasm surgery : An institutional experience

enthalten in: Revista espanola de anestesiologia y reanimacion | 2023

von Govil, N. | Tripathi, M. | Parag, K. | +3

3

Greater occipital nerve block in the treatment of headaches. Review of evidence

enthalten in: Medicina clinica | 2023

von Castillo-Álvarez, F. | Hernando de la Bárcena, I. | Marzo-Sola, M.

4

"Optimal recovery" after colon cancer surgery in the elderly, a comparative cohort study : Conventional care vs. enhanced recovery vs. prehabilitation

enthalten in: Cirugia espanola | 2023

von Cerdán Santacruz, C. | Merichal Resina, M. | Gómez Báez, F. | +9

5

Transplant Renal Artery Intervention: Analysis of a 11-Year Single Center Experience : Transplant Renal Artery Intervention: Analysis of a 11-Year Single Center Experience

enthalten in: WHO International Clinical Trials Registry Platform | 2023

6

Transplant Renal Artery Intervention: Analysis of a 11-Year Single Center Experience : Transplant Renal Artery Intervention: Analysis of a 11-Year Single Center Experience

enthalten in: WHO International Clinical Trials Registry Platform | 2023

7

Enhanced pharmaceutical recovery as postoperative standard care after radical cystectomy : A meta-analysis

enthalten in: Actas urologicas espanolas | 2022

von Ding, W. | Ji, R. | Abdelrahim, M. | +1

8

Ensayo Clínico fase 3, aleatorizado, en régimen abierto de Tanespimicina (KOS-953) más Bortezomib en comparación con Bortezomib solo, en pacientes con Mieloma Múltiple en primera recaída.Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Myeloma in First Relapse : Ensayo Clínico fase 3, aleatorizado, en régimen abierto de Tanespimicina (KOS-953) más Bortezomib en comparación con Bortezomib solo, en pacientes con Mieloma Múltiple en primera recaída.Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Myeloma in First Relapse

enthalten in: WHO International Clinical Trials Registry Platform | 2022

9

Ensayo Clínico fase 3, aleatorizado, en régimen abierto de Tanespimicina (KOS-953) más Bortezomib en comparación con Bortezomib solo, en pacientes con Mieloma Múltiple en primera recaída.Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Myeloma in First Relapse : Ensayo Clínico fase 3, aleatorizado, en régimen abierto de Tanespimicina (KOS-953) más Bortezomib en comparación con Bortezomib solo, en pacientes con Mieloma Múltiple en primera recaída.Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Myeloma in First Relapse

enthalten in: WHO International Clinical Trials Registry Platform | 2022

10

Long-term clinical outcomes of patients with nonsignificant transplanted renal artery stenosis

enthalten in: BMC nephrology | 2022

von Barteczko, M. | Orellana, H. | Santos, G. | +7

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[20]